Research programme: PPAR beta modulators - 7TM Pharma
Latest Information Update: 07 Jul 2010
At a glance
- Originator 7TM Pharma
- Class Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Lipid metabolism disorders
Most Recent Events
- 24 May 2006 CareX has been acquired and merged into 7TM Pharma
- 28 Apr 2004 Preclinical trials in Lipid metabolism disorders in France (unspecified route)